Glenmark Pharmaceuticals - Company Intelligence Profile
Industry: Pharmaceutical Manufacturing | Founded: not publicly disclosed | HQ: Mumbai, India
Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders.
Datakart tracks firmographic, hiring, traffic, technology, funding, review, and leadership signals for Glenmark Pharmaceuticals to help teams evaluate the account with useful business context.
Public company
Glenmark Pharmaceuticals
glenmarkpharma.com
Employees
15.2K
Monthly visits
237.9K
Open roles
61
Search volume
49.5K
Company Snapshot
Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders.
In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth.
We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe.
We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/
Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.
Founded
Employee count
Monthly website visits
Open roles
Company Snapshot Details
Business signals that help qualify Glenmark Pharmaceuticals
This profile combines firmographic, traffic, hiring, employee, review, compensation, technology, funding, leadership, and product availability signals so visitors can answer practical business questions without hunting across multiple data sources.
Last refreshed 2026-05-03 | 50K search volume | Domain glenmarkpharma.com
Glenmark Pharmaceuticals identity, aliases, ownership, and taxonomy
This section makes the entity easier to verify: canonical domains, alternate names, descriptions, ownership flags, parent or acquirer context, industry codes, and source-level social reach are grouped together.
Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.
Glenmark Pharma is a company that discovers advance therapies for a new world. They are creating centers of excellence in dermatology, oncology, and more.
Glenmark Pharma is discovering advance therapies for a new world. We are creating centers of excellence in dermatology, oncology and...
LinkedIn followers
1.2M
Latest linkedin followers value available from the source dataset.
Owler followers
786
Latest owler followers value available from the source dataset.
Technologies detected
201
Latest technologies detected value available from the source dataset.
Operating status
Active
Independent Company
Company type
Public Company
type
Ownership status
Public
Ownership Status
Public company
Yes
Is Public
Company alias
glenmark pharmaceuticals
Company Name Alias
Company alias
glenmark
Company Name Alias
Company alias
glenmark pharmaceuticals limited
Company Name Alias
Company alias
glenmark pharmaceuticals ltd.
Company Name Alias
Website alias
https://www.glenmarkpharma.com
Website Alias
Website alias
https://www.glenmarkpharma.com/
Website Alias
Canonical website
https://www.glenmarkpharma.com
website
Website domain
glenmarkpharma.com
Website Domain
Unique website
Yes
Unique Website
Unique domain
Yes
Unique Domain
Expired domain
No
Expired Domain
LinkedIn shorthand
glenmark-pharmaceuticals
Canonical LinkedIn Shorthand Name
Source ID
16351
Source ID
UUID
27KZ1SGXGXZE1HPW2JB2F0VPD5
uuid
SIC code
28
SIC Codes
SIC code
283
SIC Codes
NAICS code
32
NAICS Codes
NAICS code
325
NAICS Codes
Industry
Pharmaceutical Manufacturing
industry
Categories and keywords
['pharmaceuticals', 'discovery', 'innovation', 'generics', 'nces', 'nbes', 'specialty pharmaceuticals', 'specialty', 'respiratory', 'oncology', 'dermatology', 'global presence', 'health', 'biotech', 'pharma', 'biotechnology', 'health care', 'pharmaceutical']
Categories And Keywords
LinkedIn followers
1.2M
Followers Count LinkedIn
Owler followers
786
Followers Count Owler
Primary location
Glenmark House, B.D.Sawant Marg,; Chakala, Andheri (East); Mumbai, Maharashtra 400099, IN
Office location
2 Bhulabhai Desai Road; Mumbai, Maharashtra 400026, IN
Office location
B/2, Mahalakshmi Chambers, 22, Bhulabhai Desai Road; mumbai, Maharashtra, India
Office location
Andheri, Maharashtra, India
Office location
Glenmark House B. D. Sawant Marg Chakala off Western Express Highway Andheri E; Mumbai, Maharashtra 400 099, India
Office location
B. D. Sawant Marg, Chakala, Off Western Express Highway; Mumbai, 400099, India
Glenmark Pharmaceuticals revenue, funding, IPO, and acquisition history
Financial signals are grouped as an analyst-style view: revenue sources, income statement rows, funding rounds, acquisition activity, IPO fields, stock listing context, and ownership structure.
Source 5
$1.6B
Annual revenue
IPO date
2000-02-11
IPO Date
Operating status
Active
Independent Company
Company type
Public Company
type
Ownership status
Public
Ownership Status
Public company
Yes
Is Public
Q3, 2026
Q3
Primary value
Revenue: INR 38.9B
Additional metrics
Gross profit: INR 26.5B; EBITDA: INR 9.1B; EBIT: INR 5.8B; Net income: INR 4B; Operating expense: INR 17.4B; Gross margin: 68.2%; EBITDA margin: 23.5%
Q2, 2026
Q2
Primary value
Revenue: INR 60B
Additional metrics
Gross profit: INR 49.8B; EBITDA: INR 25.6B; EBIT: INR 10.3B; Net income: INR 6.1B; Operating expense: INR 24.2B; Gross margin: 83.0%; EBITDA margin: 42.6%
Q1, 2026
Q1
Primary value
Revenue: INR 30.6B
Additional metrics
Gross profit: INR 22.8B; EBITDA: INR 6.1B; EBIT: INR 1.5B; Net income: INR 469.7M; Operating expense: INR 16.7B; Gross margin: 74.4%; EBITDA margin: 19.8%
FY, 2025
Fiscal Year
Primary value
Revenue: INR 131.5B
Additional metrics
Gross profit: INR 87B; EBITDA: INR 23.9B; EBIT: INR 15.3B; Net income: INR 10.5B; Operating expense: INR 63B; Gross margin: 66.1%; EBITDA margin: 18.2%
Q3, 2025
Q3
Primary value
Revenue: INR 33B
Additional metrics
Gross profit: INR 23.3B; EBITDA: INR 6.3B; EBIT: INR 5.1B; Net income: INR 3.5B; Operating expense: INR 17B; Gross margin: 70.7%; EBITDA margin: 19.1%
Q2, 2025
Q2
Primary value
Revenue: INR 34B
Additional metrics
Gross profit: INR 24B; EBITDA: INR 6.4B; EBIT: INR 5.2B; Net income: INR 3.5B; Operating expense: INR 17.6B; Gross margin: 70.7%; EBITDA margin: 18.9%
Q1, 2025
Q1
Primary value
Revenue: INR 32.2B
Additional metrics
Gross profit: INR 21.7B; EBITDA: INR 6.2B; EBIT: INR 5B; Net income: INR 3.4B; Operating expense: INR 15.5B; Gross margin: 67.2%; EBITDA margin: 19.2%
FY, 2024
Fiscal Year
Primary value
Revenue: INR 136.5B
Additional metrics
Gross profit: INR 99B; EBITDA: INR 37.9B; EBIT: INR 10.8B; Net income: INR -14.3B; Operating expense: INR 61.1B; Gross margin: 72.6%; EBITDA margin: 27.8%
Q3, 2024
Q3
Primary value
Revenue: INR 24.6B
Additional metrics
Gross profit: INR 15.2B; EBITDA: INR -1.6B; EBIT: INR -3.9B; Net income: INR -4.9B; Operating expense: INR 16.8B; Gross margin: 61.8%; EBITDA margin: -0.1%
Q2, 2024
Q2
Primary value
Revenue: INR 28.2B
Additional metrics
Gross profit: INR 16.8B; EBITDA: INR 2.7B; EBIT: INR -1.9B; Net income: INR -3.2B; Operating expense: INR 14.2B; Gross margin: 59.7%; EBITDA margin: 9.5%
Q1, 2024
Q1
Primary value
Revenue: INR 33.4B
Additional metrics
Gross profit: INR 21.9B; EBITDA: INR 6.5B; EBIT: INR 4.5B; Net income: INR 1.7B; Operating expense: INR 15.4B; Gross margin: 65.8%; EBITDA margin: 19.5%
FY, 2023
Fiscal Year
Primary value
Revenue: INR 127.3B
Additional metrics
Gross profit: INR 85.2B; EBITDA: INR 23.6B; EBIT: INR 9.8B; Net income: INR 3.8B; Operating expense: INR 61.6B; Gross margin: 67.0%; EBITDA margin: 18.6%
| Period | Primary value | Additional metrics |
|---|---|---|
Q3, 2026 Q3 | Revenue: INR 38.9B | Gross profit: INR 26.5B; EBITDA: INR 9.1B; EBIT: INR 5.8B; Net income: INR 4B; Operating expense: INR 17.4B; Gross margin: 68.2%; EBITDA margin: 23.5% |
Q2, 2026 Q2 | Revenue: INR 60B | Gross profit: INR 49.8B; EBITDA: INR 25.6B; EBIT: INR 10.3B; Net income: INR 6.1B; Operating expense: INR 24.2B; Gross margin: 83.0%; EBITDA margin: 42.6% |
Q1, 2026 Q1 | Revenue: INR 30.6B | Gross profit: INR 22.8B; EBITDA: INR 6.1B; EBIT: INR 1.5B; Net income: INR 469.7M; Operating expense: INR 16.7B; Gross margin: 74.4%; EBITDA margin: 19.8% |
FY, 2025 Fiscal Year | Revenue: INR 131.5B | Gross profit: INR 87B; EBITDA: INR 23.9B; EBIT: INR 15.3B; Net income: INR 10.5B; Operating expense: INR 63B; Gross margin: 66.1%; EBITDA margin: 18.2% |
Q3, 2025 Q3 | Revenue: INR 33B | Gross profit: INR 23.3B; EBITDA: INR 6.3B; EBIT: INR 5.1B; Net income: INR 3.5B; Operating expense: INR 17B; Gross margin: 70.7%; EBITDA margin: 19.1% |
Q2, 2025 Q2 | Revenue: INR 34B | Gross profit: INR 24B; EBITDA: INR 6.4B; EBIT: INR 5.2B; Net income: INR 3.5B; Operating expense: INR 17.6B; Gross margin: 70.7%; EBITDA margin: 18.9% |
Q1, 2025 Q1 | Revenue: INR 32.2B | Gross profit: INR 21.7B; EBITDA: INR 6.2B; EBIT: INR 5B; Net income: INR 3.4B; Operating expense: INR 15.5B; Gross margin: 67.2%; EBITDA margin: 19.2% |
FY, 2024 Fiscal Year | Revenue: INR 136.5B | Gross profit: INR 99B; EBITDA: INR 37.9B; EBIT: INR 10.8B; Net income: INR -14.3B; Operating expense: INR 61.1B; Gross margin: 72.6%; EBITDA margin: 27.8% |
Q3, 2024 Q3 | Revenue: INR 24.6B | Gross profit: INR 15.2B; EBITDA: INR -1.6B; EBIT: INR -3.9B; Net income: INR -4.9B; Operating expense: INR 16.8B; Gross margin: 61.8%; EBITDA margin: -0.1% |
Q2, 2024 Q2 | Revenue: INR 28.2B | Gross profit: INR 16.8B; EBITDA: INR 2.7B; EBIT: INR -1.9B; Net income: INR -3.2B; Operating expense: INR 14.2B; Gross margin: 59.7%; EBITDA margin: 9.5% |
Q1, 2024 Q1 | Revenue: INR 33.4B | Gross profit: INR 21.9B; EBITDA: INR 6.5B; EBIT: INR 4.5B; Net income: INR 1.7B; Operating expense: INR 15.4B; Gross margin: 65.8%; EBITDA margin: 19.5% |
FY, 2023 Fiscal Year | Revenue: INR 127.3B | Gross profit: INR 85.2B; EBITDA: INR 23.6B; EBIT: INR 9.8B; Net income: INR 3.8B; Operating expense: INR 61.6B; Gross margin: 67.0%; EBITDA margin: 18.6% |
Post-IPO Equity
2025-07-19 | HDFC Mutual Fund
Post-IPO Equity
2018-08-13 | True North
Private Equity Round
$48M
2002-07-01 | Actis
Private Equity Round
$10M
2002-06-01 | MAPE Advisory Group
Zorg Laboratories Pvt Ltd
$7.3K
2018-07-01 | Acquisition List Source 5
Medicamenta
Acquisition
2007-03-27 | Acquisition List Source 2
Bouwer Bartlett
Acquisition
2005-12-26 | Acquisition List Source 2
Servycal
Acquisition
2005-10-26 | Acquisition List Source 2
Laboratorios Klinger
$5.2M
2004-04-02 | Acquisition List Source 2
Glenmark Pharmaceuticals FZE
Acquisition
Acquisition List Source 1
Ichnos Sciences Biotherapeutics SA
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals Kenya Ltd
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals Malaysia Sdn Bhd
Acquisition
Acquisition List Source 1
Glenmark Philippines Inc
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals Venezuela, C.A
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals Ecuador S.A.
Acquisition
Acquisition List Source 1
Glenmark Arzneimittel Gmbh - Germany
Acquisition
Acquisition List Source 1
Glenmark Farmaceutica SpA
Acquisition
Acquisition List Source 1
Glenmark Specialty SA
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals SK, S.R.O
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals S.R.O.
Acquisition
Acquisition List Source 1
Glenmark Dominicana SRL
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals Distribution S.R.O.
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals Singapore Pte. Ltd.
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals (Australia) Pty Ltd,
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals Peru SAC
Acquisition
Acquisition List Source 1
Glenmark Uruguay S.A.
Acquisition
Acquisition List Source 1
Glenmark Generics SA
Acquisition
Acquisition List Source 1
Glenmark Ukraine LLC
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals Egypt S.A.E.
Acquisition
Acquisition List Source 1
Glenmark Arzneimittel Gmbh - Austria
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals South Africa (pty) Ltd
Acquisition
Acquisition List Source 1
Glenmark Farmaceutica Ltda
Acquisition
Acquisition List Source 1
Viso Farmaceutica S.L.U.
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals SP z.o.o
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals (Nigeria) Ltd
Acquisition
Acquisition List Source 1
Ichnos Sciences Inc., USA
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals Nordic AB
Acquisition
Acquisition List Source 1
Glenmark Therapeutics Inc.
Acquisition
Acquisition List Source 1
Sintesy Pharma S.R.L
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals Mexico, S.A. DE C.V
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals Europe Ltd
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals Colombia SAS
Acquisition
Acquisition List Source 1
Glenmark Holding S. A.
Acquisition
Acquisition List Source 1
Glenmark Healthcare Limited
Acquisition
Acquisition List Source 1
Glenmark South Africa (pty) Ltd
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals Canada Inc.
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals (Thailand) Co. Ltd
Acquisition
Acquisition List Source 1
Glenmark Pharmaceuticals Inc.
Acquisition
Acquisition List Source 1
Ichnos Sciences SA
Acquisition
Acquisition List Source 1
Glenmark Impex L.L.C
Acquisition
Acquisition List Source 1
Web visibility, demand, and topics
Use these signals to understand discoverability, demand quality, search interest, and audience fit.
Monthly visits
237.9K
Latest monthly visits value available from the source dataset.
Global web rank
#172,988
Lower rank values indicate stronger web visibility in the source dataset.
Bounce rate
28.0%
Latest bounce rate value available from the source dataset.
Pages per visit
6.92
Latest pages per visit value available from the source dataset.
Average visit duration
10m 55s
Latest average visit duration value available from the source dataset.
Estimated monthly page views
1.6M
Derived estimate calculated as monthly visits multiplied by pages per visit.
glenmark
Associated search topic
glenmark pharmaceuticals
Associated search topic
glipiq
Associated search topic
gforce
Associated search topic
gforce glenmark
Associated search topic
LinkedIn followers
1.2M
Followers Count LinkedIn
Owler followers
786
Followers Count Owler
Employees, hiring, attrition, and compensation
This section groups org scale, hiring motion, employee movement, department mix, and salary benchmarks so teams can qualify operating momentum and budget signals.
Employees
15.2K
Latest employees value available from the source dataset.
Inferred employees
7.9K
Latest inferred employees value available from the source dataset.
Open roles
61
Latest open roles value available from the source dataset.
Departures
0
Latest departures value available from the source dataset.
Employee attrition rate
0.0%
Latest employee attrition rate value available from the source dataset.
Hiring intensity
4.0 roles / 1K employees
Derived signal showing open roles normalized by employee count.
Human Resources Executive
Open role
4397929493
Analista Sr. de Control de Calidad
Open role
4398495382
Manager -IPQA /QA Validation
Open role
4379684346
QMS Specialist
Open role
4398257961
Manager Finance
Open role
4399518477
Manager- Corporate Strategy
Open role
4406045889
Officer - Capital Purchase
Open role
4398450798
Assistant Medical Information Manager
Open role
4405674025
Showing 8 of 18 available records.
Showing 8 of 10 available records.
Showing 8 of 10 available records.
Document Control Specialist
USD $54K
Annual
Assistente De Qualidade
BRL $24.6K
Monthly | Updated 2023-10-26
Area Business Manager
INR $741.1K
Annual | Updated 2023-01-31
Human Resources Manager
INR $2.4M
Annual | Updated 2022-08-03
Export Logistics
INR $571.7K
Monthly | Updated 2020-06-09
Research Officer
INR $700K
Annual | Updated 2024-08-16
Propagandista Júnior
BRL $67.6K
Monthly | Updated 2024-06-06
analista microbiologia
ARS $17.7M
Monthly | Updated 2023-12-31
Showing 8 of 10 available records.
Associate Finance Director
Cash Bonus $19.3K
Annual
DGM
Cash Bonus $298.7K
Annual | Updated 2022-10-31
Director
Cash Bonus $26.6K
Annual
Sales Manager
Cash Bonus $21.7K
Annual | Updated 2023-06-07
Manager
Cash Bonus $7.6K
Annual
Representante Propagandista
Cash Bonus $184.8K; Profit Sharing $17.8K; Commission Sharing $12K
Monthly | Updated 2024-06-24
Senior Associate
Cash Bonus $7.4K
Annual
Management Trainee
Cash Bonus $96.4K
Annual | Updated 2022-08-23
Showing 8 of 10 available records.
Executive Trainee
INR $1M
Annual | Updated 2024-09-20
Medical Sales Representative
INR $975.5K
Annual | Updated 2024-09-12
Senior Research Officer
INR $1.1M
Monthly | Updated 2024-08-16
Research Officer
INR $711.1K
Annual | Updated 2024-08-16
Regulatory Affairs Specialist
INR $901.5K
Annual | Updated 2024-07-26
Asst Manager
INR $1.5M
Annual | Updated 2024-07-22
Production Officer
INR $307.3K
Annual | Updated 2024-07-19
Production
INR $257.1K
Annual | Updated 2024-07-19
Showing 8 of 10 available records.
Product readiness, customer proof, and employee sentiment
Product availability, public reviews, and employee sentiment help visitors understand whether the company is mature, documented, reviewable, and operationally healthy.
Employee reviews
821
Latest employee reviews value available from the source dataset.
Employee rating
3.5
Latest review score available from the source dataset.
Is pricing information available?
No. The source snapshot does not list pricing information for this company.
Source availability signal
Is a free trial listed?
No. The source snapshot does not list a free trial for this company.
Source availability signal
Can buyers request a demo?
No. The source snapshot does not list a demo motion for this company.
Source availability signal
Is the product downloadable?
No. The source snapshot does not list downloadable software for this company.
Source availability signal
Are mobile apps listed?
No. The source snapshot does not list mobile apps for this company.
Source availability signal
Is public documentation listed?
No. The source snapshot does not list public documentation for this company.
Source availability signal
Are online reviews listed?
No. The source snapshot does not list online reviews for this company.
Source availability signal
Technology, leadership, competitors, funding, and corporate activity
These data points help sales, partnerships, analysts, and researchers understand how the company operates, who surrounds it, and where it may be moving next.
Aos
Verified technology
Last verified 2026-05-04 | First seen 2024-05-20
Sns
Verified technology
Last verified 2026-05-04 | First seen 2024-05-20
Propio
Verified technology
Last verified 2026-05-04 | First seen 2025-08-17
Persona
Verified technology
Last verified 2026-05-04 | First seen 2025-08-17
Commvault
Verified technology
Last verified 2026-05-04 | First seen 2024-05-20
Cisco Switches
Verified technology
Last verified 2026-05-04 | First seen 2025-08-24
Ecm
Verified technology
Last verified 2026-05-04 | First seen 2026-03-10
React
Verified technology
Last verified 2026-05-04 | First seen 2025-04-08
Showing 8 of 24 available records.
Showing 8 of 12 available records.
Maria Arbuzova
PR & GR Director
Prashant kumar
Head Admin & FM
Pallavi Gadnis
DGM Marketing
Parag Naik Tuenkar
Executive
Chinmay Kinkar
Head Of Marketing
Montserrat Vega Rueda
Human Resources Head
Jogeshwer Modanwal
Executive
CA Vibha Borole
Executive
Showing 8 of 12 available records.
Digant Upadhyaya
Divison Head - Generic Business
Feb 2026
Maria Lombardi
Dirctor, Pricing and Contracts
Mar 2026
Zavy Gabriel
Head of Market
Feb 2026
Zavy Gabriel
Head of Market
Jan 2026
Ivo Winiger-Candolfi
Vice President - Medical Affairs, Global Oncology
Apr 2026
Navin Kodak
Executive
Mar 2026
Chris Huzzey
Global Head of Commercial, Respiratory and Dermatology
Mar 2026
Santosh Dayal
Head- Sales Training (India Formulations)
Apr 2026
Sudip Ghosh
Executive
Mar 2026
Sherif A.
National head of KAMs
Dec 2025
Chetan Doshi
Head - Ecommerce
Jan 2026
Natalia Dalal
HR Business Partner
Feb 2026
Primary location
Glenmark House, B.D.Sawant Marg,; Chakala, Andheri (East); Mumbai, Maharashtra 400099, IN
Office location
2 Bhulabhai Desai Road; Mumbai, Maharashtra 400026, IN
Office location
B/2, Mahalakshmi Chambers, 22, Bhulabhai Desai Road; mumbai, Maharashtra, India
Office location
Andheri, Maharashtra, India
Office location
Glenmark House B. D. Sawant Marg Chakala off Western Express Highway Andheri E; Mumbai, Maharashtra 400 099, India
Office location
B. D. Sawant Marg, Chakala, Off Western Express Highway; Mumbai, 400099, India
Every role, every effort, every hour of dedication adds up to something bigger than itself. Today, we recogni…
159 reactions; 1 comments
2026-05-01 | Every role, every effort, every hour of dedication adds up to something bigger than itself. Today, we recognise those whose commitment strengthens patients' lives, supports communities, and moves healthcare forward ever…
Glenmark recently hosted its Sales Conference in Brazil, bringing together employees across office and labora…
181 reactions; 7 comments
2026-04-27 | Glenmark recently hosted its Sales Conference in Brazil, bringing together employees across office and laboratory functions to align on the strategy and direction for the new fiscal year. The conference recognised outst…
Don’t let malaria catch you off guard! Simple preventive measures can significantly reduce your risk and help…
90 reactions; 2 comments
2026-04-25 | Don’t let malaria catch you off guard! Simple preventive measures can significantly reduce your risk and help keep you protected. #Glenmark #WorldMalariaDay
This Earth Day, we continue to move from intent to impact. We are building a more responsible footprint thro…
111 reactions; 1 comments
2026-04-22 | This Earth Day, we continue to move from intent to impact. We are building a more responsible footprint through water positivity, zero liquid discharge, plastic recycling, reducing our carbon footprint through lower en…
Glenmark Specialty S.A. marks a significant milestone with its relocation to a new office in Neuchâtel, Switz…
478 reactions; 16 comments
2026-04-20 | Glenmark Specialty S.A. marks a significant milestone with its relocation to a new office in Neuchâtel, Switzerland. The new space supports our ongoing commitment to growth and provides a strong foundation for the conti…
Not everything that’s serious looks serious. Fatty liver disease affects 1 in 3 adults globally, often withou…
105 reactions; 2 comments
2026-04-19 | Not everything that’s serious looks serious. Fatty liver disease affects 1 in 3 adults globally, often without major symptoms. This World Liver Day, take a moment for your liver. A simple check today can prevent complic…
SIC code
28
SIC Codes
SIC code
283
SIC Codes
NAICS code
32
NAICS Codes
NAICS code
325
NAICS Codes
Industry
Pharmaceutical Manufacturing
industry
Categories and keywords
['pharmaceuticals', 'discovery', 'innovation', 'generics', 'nces', 'nbes', 'specialty pharmaceuticals', 'specialty', 'respiratory', 'oncology', 'dermatology', 'global presence', 'health', 'biotech', 'pharma', 'biotechnology', 'health care', 'pharmaceutical']
Categories And Keywords
Glenmark Pharmaceuticals FAQs
Company profile
Want verified contact data for Glenmark Pharmaceuticals?
Datakart.ai gives you verified email addresses, direct dials, and buying intent signals for key decision-makers at Glenmark Pharmaceuticals and 1,700+ other companies.